Insider · CIK 0001809916
Amar Murugan
Files at ATRA (Atara Biotherapeutics, Inc.), SLRN (ACELYRIN, Inc.). First filing Nov 20, 2023, latest Mar 19, 2025.
In brief
Amar Murugan files SEC Form 4 as officer at ATRA (Atara Biotherapeutics, Inc.), and also at SLRN (ACELYRIN, Inc.). Since Nov 20, 2023, Amar Murugan has reported 0 open-market buys worth $0 and 3 open-market sells worth $21k, the latest filed on Mar 19, 2025.
A track record needs three past buys with six months of prices behind them; Amar Murugan has 0, so none is measured yet.
The newest scored trade: sold $11k of SLRN on Mar 17, 2025, filed Mar 19, 2025, scored 30 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATRA: Atara Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | ACELYRIN, Inc. | $11k 3,913 shares | -3% | - | |
| 30Weak | Atara Biotherapeutics, Inc. | $7,232 10,044 shares | -1% | +227% from low-78% from high | |
| 30Weak | Atara Biotherapeutics, Inc. | $3,231 8,307 shares | -3% | +109% from low-91% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 18, 2024 | ATRA Atara Biotherapeutics, Inc. | 1,342 0.02% of outstanding | $16k | Nov 18, 2024 | $7,677 |
| May 16, 2024 | ATRA Atara Biotherapeutics, Inc. | 34,946 0.03% of outstanding | $22k | May 16, 2024 | $7,232 |
| Mar 4, 2024 | ATRA Atara Biotherapeutics, Inc. | 10,024 0.01% of outstanding | $7,726 | Mar 4, 2024 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Common Stock | -121,587 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -525,000 | - | - | 0 | May 23, 2025 |
| Mar 17, 2025 | SLRN ACELYRIN, Inc. | SOpen-market sale Common Stock | -3,913 | $2.74 | $11k | 121,587 | Mar 19, 2025 |
| Jan 23, 2025 | SLRN ACELYRIN, Inc. | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 125,500 | Jan 24, 2025 |
| Nov 25, 2024 | SLRN ACELYRIN, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +525,000 | $0.00 | $0 | 525,000 | Nov 27, 2024 |
| Mar 4, 2024 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -10,044 | $0.72 | $7,232 | 727,521 | Mar 6, 2024 |
| Jan 8, 2024 | ATRA Atara Biotherapeutics, Inc. | AGrant or award Common Stock | +475,000 | $0.00 | $0 | 737,565 | Jan 9, 2024 |
| Nov 16, 2023 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -8,307 | $0.39 | $3,231 | 257,084 | Nov 20, 2023 |
Questions about Amar Murugan
Answered from the filings on this page, as of the latest one.
Is Amar Murugan buying or selling?
Not in the last 12 months. Amar Murugan's latest open-market trade on SEC Form 4 was sold $11k of SLRN on Mar 17, 2025.
How did Amar Murugan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Amar Murugan has 0.
Where does Amar Murugan file Form 4?
Amar Murugan has filed Form 4 at ATRA (Atara Biotherapeutics, Inc.) as EVP, Chief Legal Officer; SLRN (ACELYRIN, Inc.) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.